118 related articles for article (PubMed ID: 7365249)
1. Therapy of leukemia by nonimmune syngeneic spleen cells.
Cheever MA; Greenberg PD; Fefer A
J Immunol; 1980 May; 124(5):2137-42. PubMed ID: 7365249
[TBL] [Abstract][Full Text] [Related]
2. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
Cheever MA; Greenberg PD; Fefer A
J Immunol; 1980 Aug; 125(2):711-4. PubMed ID: 6156213
[TBL] [Abstract][Full Text] [Related]
3. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
Cheever MA; Greenberg PD; Fefer A
Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
[TBL] [Abstract][Full Text] [Related]
4. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
Berenson JR; Einstein AB; Fefer A
J Immunol; 1975 Jul; 115(1):234-8. PubMed ID: 1080165
[TBL] [Abstract][Full Text] [Related]
5. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
Nio Y; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
7. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Einstein AB; Fass L; Fefer A
Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
[TBL] [Abstract][Full Text] [Related]
8. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
Gordon WC; Prager MD
Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
[TBL] [Abstract][Full Text] [Related]
9. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
11. Use of adoptive transfer and Winn assay procedures in the further analysis of antiviral acquired immunity in mice protected against Friend leukemia virus-induced disease by passive serum therapy.
Genovesi EV; Pettey CL; Collins JJ
Cancer Res; 1984 Apr; 44(4):1489-98. PubMed ID: 6608407
[TBL] [Abstract][Full Text] [Related]
12. Effector mechanism of tumor immunity in murine plasmacytoma.
Chen YH; Anderson AB
Cancer Res; 1988 Mar; 48(6):1398-403. PubMed ID: 3257896
[TBL] [Abstract][Full Text] [Related]
13. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.
Greenberg PD; Cheever MA
J Immunol; 1984 Dec; 133(6):3401-7. PubMed ID: 6149246
[TBL] [Abstract][Full Text] [Related]
14. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
[TBL] [Abstract][Full Text] [Related]
15. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
16. Passive transfer of systemic tumor immunity with cells generated in vitro by a secondary immune response to a syngeneic rat gross virus-induced lymphoma.
Bernstein ID
J Immunol; 1977 Jan; 118(1):122-8. PubMed ID: 830744
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
Ujiie T
Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
[TBL] [Abstract][Full Text] [Related]
18. Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: effect of culture duration on therapeutic efficacy.
Cheever MA; Greenberg PD; Fefer A
J Natl Cancer Inst; 1981 Jul; 67(1):169-73. PubMed ID: 6942187
[TBL] [Abstract][Full Text] [Related]
19. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
Vallera DA; Mentzer SJ; Maizel SE
Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
[TBL] [Abstract][Full Text] [Related]
20. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA
J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
